核苷(酸)类似物耐药机制及突变位点研究进展  

Research Progress on Nucleos(t)ide Analogues Resistance Mechanism and Mutation Sites

作　　者：李原华 葛斐林 陈容娟 柏兆方 李乐 赵靖 刘妍 刘文龙[1] 肖小河 LI Yuanhua;GE Feilin;CHEN Rongjuan;BAI Zhaofang;LI Le;ZHAO Jing;LIU Yan;LIU Wenlong;XIAO Xiaohe(College of Pharmacy,Hunan University of Traditional Chinese Medicine,Changsha Hunan 410208,China;Department of Infectious Diseases,Fifth Medical Center of Chinese PLA General Hospital,Beijing 100039,China;Department of Hepatology,Fifth Medical Center of Chinese PLA General Hospital,Beijing 100039,China;School of Chinese Materia Medica,Beijing University of Traditional Chinese Medicine,Beijing 100029,China)

机构地区：[1]湖南中医药大学药学院,湖南长沙410208 [2]解放军总医院第五医学中心感染病医学部,北京100039 [3]解放军总医院第五医学中心肝病医学部,北京100039 [4]北京中医药大学中药学院,北京100029

出　　处：《中国药物警戒》2021年第8期795-799,共5页Chinese Journal of Pharmacovigilance

基　　金：国家自然科学基金资助项目(81930110);国家自然科学基金面上项目(81573676)。

摘　　要：核苷(酸)类似物(nucleos(t)ide analogues,NAs)耐药乙型肝炎病毒(hepatitis B virus,HBV)感染是由长期使用药物后HBV逆转录酶区的基因突变导致。耐药性的出现可导致治疗失败,也是疾病进展的重要原因之一。阐明HBV耐药机制对于药物选择及预后治疗具有重要帮助;梳理HBV耐药的突变位点现状将为进一步探讨耐药HBV的相关风险信号及临床精准防控提供依据。本文就NAs耐药乙肝的分子机制与突变位点研究进行简要综述,旨在为耐药乙肝的治疗提供参考。Nucleos(t)ide analogues(NAs)-resistant hepatitis B is caused by gene mutations in the reverse transcriptase region of hepatitis B virus(HBV)after long-term use of NAs.NAs resistance could lead to treatment failure,and it is also one of the important reasons for liver disease progression.Clarifying the mechanism of HBV NAs resistance is of great help to strategy selection and prognosis treatment;combing the mutation site of HBV NAs resistance will provide the basis for further exploring the risk signals of drugresistant hepatitis B and clinical precise prevention and control.This review analyzed the molecular mechanism and mutation site of NAs-resistant hepatitis B,hoping to provide a reference for the prevention and treatment of NAs-resistant hepatitis B.

关 键 词：慢性乙型病毒性肝炎 核苷(酸)类似物 耐药变异 分子机制 突变位点 风险信号 

分 类 号：R978.7[医药卫生—药品]